Earnings playREGN’s chart shows a classic dip in a long-term uptrend, with FDA tailwinds and undervaluation (14x PE vs. sector 25x) making it a compelling buy. The $560–$570 zone offers a low-risk entry ahead of earnings, where a beat could ignite a 20–30% rally to $700+. Buy on dip for 10–15% short-term gain, w
Regeneron Pharmaceuticals, Inc.Shs Unsponsored Brazilian Depositary Receipt Repr 0.0166667 Sh
No trades
Key facts today
Formycon's shares rose approximately 8% following the announcement of its FYB208 drug as a biosimilar candidate for Dupixent, which is produced by Regeneron Pharmaceuticals in partnership with Sanofi.
15,800.00
0.00 BRL
23.79 B BRL
76.56 B BRL
About Regeneron Pharmaceuticals, Inc.
Sector
Industry
CEO
Leonard S. Schleifer
Website
Headquarters
Tarrytown
Founded
1988
ISIN
BRREGNBDR005
FIGI
BBG00P14K7Y9
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Related stocks
Regeneron $563 BuyMy main reason for taking a position in this is that Michael Bury has taken a large position in the stock.
The daily chart suggests that the stock has bottomed, the 50 day m/a is now starting to curve upwards and price is now sitting on the 100 day m/a, the 200 day m/a currently at just over $600.
L
Can Innovation Survive Manufacturing Chaos?Regeneron Pharmaceuticals stands at a fascinating crossroads, embodying the paradox of modern biotechnology: extraordinary scientific achievement shadowed by operational vulnerability. The company has successfully transformed from a blockbuster-dependent enterprise into a diversified biopharmaceutic
Looking for lower on REGN. Will long in my box. Looking for a little lower on REGN. I am looking to long if we get to the major fib level and yearly level. But I will not just buy once we get there (first touch trade). I would wait to see how price action is looking. Will there be any major resistance that we set up on the way down that will
REGN Weekly Trade Setup – High Conviction Put Play
🎯 **REGN Weekly Trade Setup – High Conviction Put Play**
📌 **Instrument:** REGN
📉 **Direction:** PUT (SHORT)
💵 **Strike:** \$580
💰 **Entry Price:** \$5.20
🏹 **Profit Target:** \$10.40
🛑 **Stop Loss:** \$7.80
📅 **Expiry:** 2025-08-20
📏 **Size:** 1
💪 **Confidence:** 65%
⏰ **Entry Timing:** Market O
Regeneron Pharmaceuticals | REGN | Long at $502.28Regeneron Pharmaceuticals NASDAQ:REGN stock dropped more than 17% today due to mixed Phase 3 trial results for itepekimab, a potential COPD drug. However, the company has an extensive drug pipeline, raked in over $14 billion last year, and is currently trading at a price-to-earnings of 15x. Debt-t
REGN | Regeneron Pharmaceuticals – Macro Reaccumulation SetupPublished by WaverVanir International LLC | 06/12/2025
Regeneron has completed a deep retracement, touching the 0.886 Fibonacci level (~$567) and entering a strong discount zone, coinciding with a weak low sweep and increasing volume — suggesting potential accumulation by institutions.
🔍 Key Confl
Regeneron Pharmaceuticals Q2-Q3 Confirmed "Troughing in ProgressIF we do not crash like many Elliottsions are suggesting implying of Grand 5th wave since 1929...
iF we do not start WW3...
IF everything utterly absolute out there in the pharmaceutical industries locally
and globally...
IF our studies of the relation between XLV and Regeneron Pharmaceuticals is
r
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
REGN5027988
Regeneron Pharmaceuticals, Inc. 2.8% 15-SEP-2050Yield to maturity
5.71%
Maturity date
Sep 15, 2050
REGN5027987
Regeneron Pharmaceuticals, Inc. 1.75% 15-SEP-2030Yield to maturity
4.39%
Maturity date
Sep 15, 2030
See all REGN34 bonds
Curated watchlists where REGN34 is featured.











